Therefore, the elaboration of novel clinical practice guidelines have established a non-invasive diagnostic strategy for patients with cardiac amyloidosis based on the Perugini score, stating that a score of 2 or 3 and the absence of blood dyscrasia, represent enough evidence for TTR cardiac amyloidosis diagnosis [14]. This evidence concerns the gene TTR and dysplasia.